FDA — authorised 18 August 2023
- Marketing authorisation holder: REGENERON PHARMACEUTICALS
- Status: approved
🇺🇸 Veopoz in United States
FDA authorised Veopoz on 18 August 2023
Marketing authorisations
FDA — authorised 18 August 2023
- Application: BLA761339
- Marketing authorisation holder: REGENERON PHARMACEUTICALS
- Local brand name: VEOPOZ
- Indication: INJECTABLE — INJECTION
- Status: approved
Veopoz in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Veopoz approved in United States?
Yes. FDA authorised it on 18 August 2023; FDA authorised it on 18 August 2023.
Who is the marketing authorisation holder for Veopoz in United States?
REGENERON PHARMACEUTICALS holds the US marketing authorisation.